Steele Labs :: Publications

Hwang WL, Jagadeesh KA, Guo JA, Hoffman HI, Yadollahpour P, Reeves JW, Mohan R, Drokhlyansky E, Van Wittenberghe N, Ashenberg O, Farhi SL, Schapiro D, Divakar P, Miller E, Zollinger DR, Eng G, Schenkel JM, Su J, Shiau C, Yu P, Freed-Pastor WA, Abbondanza D, Mehta A, Gould J, Lambden C, Porter CBM, Tsankov A, Dionne D, Waldman J, Cuoco MS, Nguyen L, Delorey T, Phillips D, Barth JL, Kem M, Rodrigues C, Ciprani D, Roldan J, Zelga P, Jorgji V, Chen JH, Ely Z, Zhao D, Fuhrman K, Fropf R, Beechem JM, Loeffler JS, Ryan DP, Weekes CD, Ferrone CR, Qadan M, Aryee MJ, Jain RK, Neuberg DS, Wo JY, Hong TS, Xavier R, Aguirre AJ, Rozenblatt-Rosen O, Mino-Kenudson M, Castillo CF, Liss AS, Ting DT, Jacks T, Regev A

Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment.

Nat Genet. 2022;54(8):1178-1191 - PMID: 35902743 - DOI: 10.1038/s41588-022-01134-8

How J, Ren S, Lombardi-Story J, Bergeron M, Foster J, Amrein PC, Brunner AM, Fathi AT, Hock H, Khachatryan A, Kikuchi H, Ng MR, Moran J, Narayan R, Neuberg D, Ramos A, Som T, Vartanian M, Chen YB, Duda DG, Hobbs GS

A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies.

EJHaem. 2022;3(2):434-442 - PMID: 35846042 - PMCID: PMC9175677 - DOI: 10.1002/jha2.408

Saulnier Sholler G, Duda DG, Bergendahl G, Ebb D, Snuderl M, Laetsch TW, Michlitsch J, Hanson D, Isakoff MS, Bielamowicz K, Kraveka JM, Ferguson W, Carmeliet P, De Deene A, Gijsen L, Jain RK

A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma.

Clin Cancer Res. 2022;:ePub - PMID: 35833850 - DOI: 10.1158/1078-0432.CCR-22-1169

Ho WW, Pittet MJ, Fukumura D, Jain RK

The local microenvironment matters in preclinical basic and translational studies of cancer immunology and immunotherapy.

Cancer Cell. 2022;40(7):701-702 - PMID: 35714604 - DOI: 10.1016/j.ccell.2022.05.016

Morita S, Duda DG

Refining genetic and molecular classifications to facilitate breakthrough treatments in intrahepatic cholangiocarcinoma: are we there yet?

Gut. 2022;:ePub - PMID: 35772925 - DOI: 10.1136/gutjnl-2022-327782

Nuzzo PV, Adib E, Weise N, Curran C, Stewart T, Freeman D, Nassar AH, Abou Alaiwi S, Bakouny Z, McGregor BA, Choueiri TK, Jain RK, McKay RR, Sonpavde G

Impact of renin-angiotensin system inhibitors on outcomes in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors

Clin Genitourin Cancer. 2022;20(4):301-306 - PMID: 35614012 - DOI: 10.1016/j.clgc.2022.04.012

van den Bent L, Frenkel NC, Poghosyan S, Molenaar IQ, Padera TP, Kranenburg O, Borel Rinkes IHM, Hagendoorn J

Liver lymphatic drainage patterns follow segmental anatomy.

Br J Surg. 2022;109(6):559-560 - PMID: 35576376 - DOI: 10.1093/bjs/znac076

Martin JD, Lanning RM, Chauhan VP, Martin MR, Mousa AS, Kamoun WS, Han HS, Lee H, Stylianopoulos T, Bawendi MG, Duda DG, Brown EB, Padera TP, Fukumura D, Jain RK

Multiphoton phosphorescence quenching microscopy reveals kinetics of tumor oxygenation during anti-angiogenesis and angiotensin signaling inhibition.

Clin Cancer Res. 2022;28(14):3076-3090 - PMID: 35584239 - DOI: 10.1158/1078-0432.CCR-22-0486

Jones D, Wang Z, Chen I, Zhang S, Banerji R, Lei PJ, Zhou H, Xiao V, Kwong C, Van Wijnbergen JW, Pereira E, Vakoc B, Huang P, Nia H, Padera T

Solid stress impairs lymphocyte infiltration into lymph node metastases.

FASEB J. 2022;36 Suppl 1:ePub - PMID: 35557097 - DOI: 10.1096/fasebj.2022.36.S1.R4616

Pu Z, Duda DG, Zhu Y, Pei S, Wang X, Huang Y, Yi P, Huang Z, Peng F, Hu X, Fan X

VCP interaction with HMGB1 promotes hepatocellular carcinoma progression by activating the PI3K/AKT/mTOR pathway.

J Transl Med. 2022;20(1):212 - PMID: 35562734 - PMCID: PMC9102726 - DOI: 10.1186/s12967-022-03416-5

Zhao F, Chen Y, Li SW, Zhang J, Zhang S, Zhao XB, Yang ZJ, Wang B, He QY, Wang LM, Xu L, Liu PN

Novel patient-derived xenograft and cell line models for therapeutic screening in NF2-associated schwannoma.

J Pathol. 2022;257(5):620-634 - PMID: 35394061 - DOI: 10.1002/path.5908

Agrud A, Subburaju S, Goel P, Ren J, Kumar AS, Caldarone BJ, Dai W, Chavez J, Fukumura D, Jain RK, Kloner RA, Vasudevan A

Gabrb3 endothelial cell-specific knockout mice display abnormal blood flow, hypertension, and behavioral dysfunction.

Sci Rep. 2022;12(1):4922 - PMID: 35318369 - PMCID: PMC8941104 - DOI: 10.1038/s41598-022-08806-9

Baish JW, Padera TP, Munn LL

The effects of gravity and compression on interstitial fluid transport in the lower limb.

Sci Rep. 2022;12(1):4890 - PMID: 35318426 - PMCID: PMC8941011 - DOI: 10.1038/s41598-022-09028-9

Kikuchi H, Matsui A, Morita S, Amoozgar Z, Inoue K, Ruan Z, Staiculescu D, Wong JS, Huang P, Yau T, Jain RK, Duda DG

Increased CD8+ T-Cell Infiltration and Efficacy for Multikinase Inhibitors after PD-1 Blockade in Hepatocellular Carcinoma.

J Natl Cancer Inst. 2022;:ePub - PMID: 35288743 - DOI: 10.1093/jnci/djac051

Mpekris F, Voutouri C, Panagi M, Baish JW, Jain RK, Stylianopoulos T

Normalizing tumor microenvironment with nanomedicine and metronomic therapy to improve immunotherapy

Journal of Controlled Release. 2022;345:190-199 - PMID: 35271911 - PMCID: PMC9168447 - DOI: 10.1016/j.jconrel.2022.03.008

Souri M, Soltani M, Moradi Kashkooli F, Kiani Shahvandi M, Chiani M, Shariati FS, Mehrabi MR, Munn LL

Towards principled design of cancer nanomedicine to accelerate clinical translation.

Mater Today Bio. 2022;13:100208 - PMID: 35198957 - PMCID: PMC8841842 - DOI: 10.1016/j.mtbio.2022.100208

Hauth F, Roberts HJ, Hong TS, Duda DG

Leveraging Blood-Based Diagnostics to Predict Tumor Biology and Extend the Application and Personalization of Radiotherapy in Liver Cancers.

Int J Mol Sci. 2022;23(4):ePub - PMID: 35216045 - PMCID: PMC8879105 - DOI: 10.3390/ijms23041926

Chamseddine I, Kim Y, De B, El Naqa I, Duda DG, Wolfgang J, Pursley J, Paganetti H, Wo J, Hong T, Koay EJ, Grassberger C

Predictive Modeling of Survival and Toxicity in Patients With Hepatocellular Carcinoma After Radiotherapy.

JCO Clin Cancer Inform. 2022;6:e2100169 - PMID: 35192402 - PMCID: PMC8863122 - DOI: 10.1200/CCI.21.00169

Xiao Y, Chen J, Zhou H, Zeng X, Ruan Z, Pu Z, Jiang X, Matsui A, Zhu L, Amoozgar Z, Chen DS, Han X, Duda DG, Shi J

Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy.

Nat Commun. 2022;13(1):758 - PMID: 35140208 - PMCID: PMC8828745 - DOI: 10.1038/s41467-022-28279-8

Moran H, Cancel LM, Huang P, Roberge S, Xu T, Tarbell JM, Munn LL

Glycocalyx mechanotransduction mechanisms are involved in renal cancer metastasis.

Matrix Biol Plus. 2022;13:100100 - PMID: 35106474 - PMCID: PMC8789524 - DOI: 10.1016/j.mbplus.2021.100100

Drobni ZD, Michielin O, Quinaglia T, Zlotoff DA, Zubiri L, Gilman HK, Supraja S, Merkely B, Muller V, Sullivan RJ, Reynolds KL, Pittet MJ, Jain RK, Neilan TG

Renin–angiotensin–aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors

European Journal of Cancer. 2022;163:108-118 - PMID: 35065368 - DOI: 10.1016/j.ejca.2021.12.024

Subudhi S, Voutouri C, Hardin CC, Nikmaneshi MR, Patel AB, Verma A, Khandekar MJ, Dutta S, Stylianopoulos T, Jain RK, Munn LL

Strategies to minimize heterogeneity and optimize clinical trials in Acute Respiratory Distress Syndrome (ARDS): Insights from mathematical modelling

EBioMedicine. 2022;75:103809 - PMID: 35033853 - PMCID: PMC8757652 - DOI: 10.1016/j.ebiom.2021.103809